Definitive Contract 75N93024C00014
Award Date 9/1/24
Potential Completion Date 8/31/26
Potential Value $595K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Buffalo, NY 14203, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
- This is a $30,320,960.00 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the establishment of mRNA vaccine capability in support of NIAID's Vaccine Research Center (VRC) programs. The contract is a cost-plus-fixed-fee type with a period of performance through June 17, 2030. There is no set-aside...
- This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
- This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Profectus Biosciences, Inc., a small business concern, for the development of novel vaccine technologies and strategies. The contract has a total potential value of $322,336.00 and was awarded under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed...
- This definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Celdara Medical of Lebanon, New Hampshire. With a value of $599,977, the firm fixed price contract supports research under Solicitation Number NIH-CDC-SBIR-2019 in adjuvant development for vaccines against infectious or immune-mediated diseases. Specifically, the prime contractor will conduct work requested under Topic 081 of the solicitation, which sought small...
- This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases, under NIAID's Broad Agency Announcement (BAA) Research Area 001. AAHI...
- This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $3,050,014.00 contract is for research, development, and production of mRNA vaccine antigens. This contract does not have a set-aside designation. Leidos Biomedical Research Inc. provides a broad range of research, development, and production services to...
- This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
- The National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, awarded a $10,650.00 firm fixed-price purchase order contract to Scale Biosciences, Inc. for the procurement of RNA kits. This contract has a total small business set-aside designation and a period of performance through December 31, 2024. As NIAID is responsible for conducting and supporting research to understand, treat, and prevent infectious diseases, this contract award is likely related to their...
- This is a firm fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to IDT Biologika GMBH, a German biotechnology company. The $1,366,000 contract is for the development, manufacturing, and characterization of various biological materials to support infectious disease research and pandemic preparedness efforts, including influenza virus human challenge material, Staphylococcus aureus...